Risperidone for autism spectrum disorder
Referencias
Additional references
Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. The Cochrane Library, Issue 1. Chichester UK: John Wiley & Sons, Ltd, 2004.
Aman M, Singh N. Aberrant Behaviour Checklist; Manual. New York: Slosson Educational Publications, 1986.
Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioural symptoms. Americal Journal of Psychiatry 1984;141:1195‐1202.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). Fourth. Washington DC: American Psychiatric Association, 1994.
British Medical Association. British National Formulary. Royal Pharmaceutical Society of Great Britain, 2003.
Bryson B, Rogers D, Fombonne E. Autism Spectrum disorders: early detection, intervention, education and psychopharmacological management. Canadian Journal of Psychiatry 2003;48(8):506‐516.
Campbell M, Armenteros JL, Malone LP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic‐ related dyskinesias in autistic children: a prospective longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 1997;17:640‐655.
Campbell M, Rapport JL, Simpson GM. Anitpsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 1999;38:537‐545.
Croen LA, Grether JK, Hoogstrate J, Selvin S. Changes in the prevalence of autism. Journal of Autism 2002;32(3):207‐215.
Egger M, Davey‐Smith, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315 (7109):629‐634.
Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin 1997;33(1):155‐159.
Fombonne E. The epidemiology of autism: a review. Psychological Medicine 1999;29:769‐786.
Gringas P. Practical paediatric psychopharmacological prescribing in autism. Autism 2000;4(3):229‐247.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐1558.
Katona C, Robertson M. Psychiatry at a glance. Second Edition. Oxford: Blackwell Science, 2000.
Krug DA, Arick J, Almond P. Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. Journal of Child Psychology and Psychiatry 1980;21:221‐229.
Lissauer T, Claydon G. Illustrated textbook of paediatrics. Second Edition. London: Mosby, 2002.
Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E. Autism Diagnostic Observation Schedule (ADOS). Journal of Autism and Developmental Disorders 1989;19(2):185‐212.
Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview ‐ Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 1994;24:659‐685.
Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opinion on Pharmacotherapy 2001;2(4):587‐600.
Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treamtnet of children, adolescents and adults with pervasive developmental disorders: an open‐labelled pilot study. Journal of Clinical Psychopharmacology 1999;19:37‐44.
Schopler E, Reichler R, Renner BR. Child Autism Rating Scale. Los Angeles: Western Psychological Services, 1988.
Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, Place M. The Developmental, Dimensional and Diagnostic Interview (3di): A Novel Computerized Assessment for Autism Spectrum Disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(5):548‐558.
World Health Organisation. The ICD‐10 Classification of Mental and Behaviour Disorders: Diagnostic Criteria for Research. Geneva: World Health Organisation, 1993.
Wing L. Diagnostic Interview for Social and Communication Disorders. Tenth. London: The National Autistic Society, 1999.
